| Patient | Dorothea Lange |
|---|---|
| Date of birth | 1964-05-26 |
| Identifiers | MRN HR-ML045-SYN; SSN (made up) 000-45-9127 |
| Document date | 2026-05-18 |
| Author | Gwendolyn Ashford-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Endoscopy results; post-polio syndrome follow-up. [S]
Ms. Lange had an upper endoscopy two and a half weeks ago, three and a half weeks after her last omeprazole dose, under moderate sedation at reduced doses with oxygen and carbon dioxide monitoring and warming; she recovered without any fall in oxygen saturation. It showed Los Angeles grade B esophagitis and a 2 cm sliding hiatal hernia, with a regular junction and no Barrett's esophagus; the stomach showed healed changes of her ulcer operation and no ulcer, and the gastric biopsies showed no Helicobacter pylori. The fever and aching after the zoledronic acid infusion settled in three days. Heartburn continues on four or five nights a week on antacid tablets. Physical therapy ends next week; she has learned her home program. No falls. She is printing in the darkroom for an exhibition and photographing two days a week. [S]
| Element | Detail |
|---|---|
| Endoscopy | LA grade B esophagitis; 2 cm hiatal hernia; no Barrett's esophagus; no Helicobacter pylori |
| Sedation | Reduced doses tolerated without desaturation |
| After zoledronic acid | Acute-phase reaction for three days, resolved |
| Function | No falls; physical therapy ending next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight stable |
| Gastrointestinal | Positive | Heartburn four or five nights a week; no difficulty swallowing, vomiting, or black stools |
| Musculoskeletal | Positive | Mild thigh aching after field days |
| Neurological | Negative | No new weakness |
| Respiratory | Negative | No breathlessness |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for muscle aching, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2025-06-02 | active | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth 30 to 60 minutes before breakfast, an eight-week trial for heartburn | One capsule once daily before breakfast | Oral route | 2026-02-09 to 2026-04-06 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, two tablets (2000 units) by mouth once daily | Two tablets once daily | Oral route | 2026-02-25 | active | S |
| Calcium carbonate 500 mg chewable tablet, one or two tablets by mouth as needed for heartburn, no more than six tablets a day, while off omeprazole before the endoscopy | One or two tablets up to every 4 hours as needed | Oral route | 2026-04-20 to 2026-05-18 | completed | S |
| Zoledronic acid 5 mg in 100 mL intravenous infusion over at least 15 minutes once a year | One infusion once a year | Intravenous route | 2026-04-20 | active | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth before breakfast for eight weeks to heal esophagitis, then the lowest dose that controls symptoms | One capsule once daily before breakfast | Oral route | 2026-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-18 | Body height | 152 | cm | S |
| 2026-05-18 | Body weight | 50.8 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 70 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S |
Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Soft; no tenderness |
| Neurological | Strength unchanged: left quadriceps 4/5, right quadriceps 3+/5 |
| Gait | Steady with the orthosis and cane; Timed Up and Go 11.5 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| New fatigue and slowly increasing weakness for about 18 months, in the left leg and both arms as well as the right leg weakened by polio at seven, with aching muscle pain after work and cold intolerance of the right leg; cause to be established | resolved | confirmed | M62.81 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of post-polio syndrome at the second visit; the paralytic polio of 1902 is documented (D). |
| Post-polio syndrome (modified March of Dimes criteria met): new weakness of the left quadriceps and both shoulder girdles and increased weakness of the right leg, with fatigue, muscle pain, and cold intolerance, more than 50 years after paralytic polio with partial recovery and decades of stable function; nerve conduction normal; EMG chronic reinnervation in both legs and the right deltoid; other causes excluded | active | confirmed | G14 | S — Synthetic modern diagnosis; the childhood polio is documented (D), and her biographer's account of post-polio symptoms later in life is a retrospective interpretation (R). No neurological finding from her lifetime is used. |
| Heartburn and regurgitation after meals and at night for three months, three to four times a week; no difficulty swallowing, weight loss, vomiting, bleeding, or anemia | resolved | confirmed | R12 | S — Synthetic presenting symptom at the index visit, superseded by the endoscopic diagnosis at the fourth visit. |
| Gastroesophageal reflux disease with Los Angeles grade B erosive esophagitis on upper endoscopy off proton pump inhibitor; no Barrett's esophagus | active | confirmed | K21.00 | S — Synthetic endoscopic diagnosis; it does not echo or foreshadow her later documented illness. |
| Small (2 cm) sliding hiatal hernia on upper endoscopy | active | confirmed | K44.9 | S — Synthetic endoscopic finding. |
| Osteoporosis, worst at the right hip on the polio-weakened side (right femoral neck T-score -2.7; left -1.6; lumbar spine -1.8), with vitamin D insufficiency; no vertebral fracture on assessment; 10-year FRAX risk about 16 percent major osteoporotic and 4.5 percent hip | active | confirmed | M81.8 | S — Synthetic bone density result; disuse of a polio-affected limb lowers bone density on that side. |
| Two falls in the past year without injury, from catching the right foot | active | confirmed | Z91.81 | S — Synthetic fall history at presentation. |
| Surgery for severe stomach ulcers in her early fifties; no ulcer symptoms since; avoids nonsteroidal anti-inflammatory drugs | active | confirmed | Z87.11 | S — Synthetic modern history entry linked to the documented ulcers and surgery of the late 1940s (D); the type of operation is not known. |
| Acute-phase reaction two days after the first zoledronic acid infusion: fever to 38.1 °C, muscle and joint aching, and headache, without signs of infection; calcium normal; resolved in three days with acetaminophen and fluids | resolved | confirmed | T50.995A | S — Synthetic expected adverse effect of a first intravenous bisphosphonate dose. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Upper endoscopy off proton pump inhibitor | When symptoms return after stopping | Up to date | Two and a half weeks ago: LA grade B esophagitis; 2 cm hiatal hernia; no Barrett's esophagus |
| Laboratory | Gastric biopsies for Helicobacter pylori | At endoscopy | Up to date | Negative |
| Imaging | Barrett's esophagus surveillance | Only if Barrett's esophagus is found | Not indicated | None found; fewer than three risk factors; no repeat screening after a negative examination |
| Medication safety | Proton pump inhibitor dose | Healing course, then the lowest effective dose | Completed today | Omeprazole 20 mg daily for eight weeks; step-down planned |
| Self-management | Reflux lifestyle measures | Every visit | Completed today | Last meal three hours before bed; head of bed raised |
| Medication safety | Sedation precautions | Before any procedure | Up to date | Endoscopy under reduced-dose sedation without desaturation |
| Examination | Manual muscle testing and Timed Up and Go | Every visit | Completed today | Strength unchanged; TUG 11.5 seconds |
| Survey | Pain score | Every visit | Completed today | Pain 4 of 10 |
| Survey | Depression screen (PHQ-9) | Periodically | Completed today | PHQ-9 3 |
| Referral | Supervised non-fatiguing exercise (physical therapy) | Twelve weeks | Up to date | Ends next week; home program learned |
| Examination | Swallowing screen | Every visit | Completed today | No difficulty swallowing |
| Examination | Fall review | Every visit | Completed today | No falls |
| Medication safety | Zoledronic acid tolerance | After each infusion | Completed today | Acute-phase reaction for three days after the first dose; calcium normal at the sick visit |
| Laboratory | 24-hour urine calcium | At diagnosis | Due | Kit reissued; to be collected before the yearly review |
Goal progress:
Guideline basis: EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol 2006;13(8):795-801 (2006); ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022;117(1):27-56 (2022); Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol 2022;117(4):559-587 (2022)
Follow-up: Omeprazole for eight weeks, then step down. Primary care review in three months. Next scheduled visit 2026-08-17: six-month review of post-polio syndrome, falls, bone health, and reflux step-down. [S]